1. TPST-1120 3 tablets (600 mg) by mouth twice a day every day along with atezolizumab 1200 mg intravenously every 3 weeks and bevacizumab 15 mg/kg intravenously every 3 weeks 2. Placebo (look-alike that does not contain study drug) 3 tablets by mouth twice a day every day along with...
The safety of atezolizumab plus bevacizumab (atezo/bev) treatment in Chinese patients (pts) with hepatocellular carcinoma (HCC) with active hepatitis B virus (HBV) infection: Results from the TALENTop study.doi:10.1200/JCO.2024.42.16_suppl.e16168...
Protocol-defined dose limiting toxicity (DLT) criteria included standard grade Z3 or 4 haematologic and non-haematologic toxicities. Dosing commenced with the recommended phase 2 dose of atezolizumab administered in combination with the labelled q3w dose of bevacizumab, and no DLTs were reported. ...
Genomics and proteomics to determine novel molecular subtypes and predict the response to immunotherapy and the effect of bevacizumab in glioblastoma Dongdong Luo Aiping Luo Biao Peng Scientific Reports (2024) Siglec-15 on macrophages suppress the immune microenvironment in patients with PD-L1 negativ...
(Atezo) plus bevacizumab (Bev) is the preferred first-line treatment of HCC patients with BCLC stage C.20–22 The IMbrave150 trial established the position of Atezo-Bev as the first-line treatment for advanced HCC.20 However, the patients with large uHCC were underrepresented in the IMbrave...
In IMpower150, patients were randomly assigned 1:1:1 to receive atezolizumab plus bevacizumab plus carboplatin and paclitaxel, atezolizumab plus carboplatin and paclitaxel, or bevacizumab plus carboplatin and paclitaxel, followed by maintenance therapy with atezolizumab plus bevacizumab, atezolizumab, or beva...
Bevacizumab was previously found to delay or prevent progression of brain metastases in NSCLC.28,29 Therefore, we also present results from exploratory post hoc analyses evaluating the rate and time to development of new lesions in the brain in the ABCP or ACP arm versus the BCP arm, ...
Journal of Hepatocellular Carcinoma Dovepress open access to scientific and medical research Open Access Full Text Article ORIGINAL RESEARCH Serum IGF-1 Scores and Clinical Outcomes in the Phase III IMbrave150 Study of Atezolizumab Plus Bevacizumab versus Sorafenib in Patients with Unresectable ...
1-3 Bevacizumab and olaparib are the only approved targeted therapies for selected patients, where available.29,30 This is the first study to report long-term and landmark OS rates at 2 years or longer in patients with mTNBC who received a PD-L1/PD-1 inhibitor. The median OS in ...
Genentech, Inc., a member of the Roche Group, sponsored the study and supplied the drugs atezolizumab and bevacizumab. Approval for the protocol and its subsequent amendments were obtained from the appropriate institutional review boards or ethics committees. This study was done in compliance with th...